Dexcom (DXCM) EPS (Basic) (2010 - 2026)

Dexcom (DXCM) has reported EPS (Basic) for 17 consecutive years, with $0.65 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EPS (Basic) rose 42.13% year-over-year to $0.65 in Q2 2026; TTM through Jun 2026 was $2.62, a 79.46% increase from a year earlier, with the FY2025 full-year figure at $2.14, up 46.41% from the prior year.
• EPS (Basic) was $0.65 for Q2 2026 at Dexcom, up from $0.52 in the prior quarter.
• Over five years, EPS (Basic) peaked at $0.73 in Q3 2025 and troughed at $0.13 in Q1 2023.
• A 5-year average of $0.39 and a median of $0.35 in 2024 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) soared 1820.51% in 2022 and sank 49.78% in 2023, its largest moves.
• Over 5 years, EPS (Basic) stood at $0.24 in 2022, then jumped by 181.65% to $0.66 in 2023, then plunged by 41.95% to $0.39 in 2024, then soared by 77.74% to $0.69 in 2025, then retreated by 4.86% to $0.65 in 2026.
• The last three EPS (Basic) figures came in at $0.65 (Q2 2026), $0.52 (Q1 2026), and $0.69 (Q4 2025), per Business Quant data.